Viewing nowCombinationJemimet Extended Release Tablets 25/750 mg (Jemigliptin, Metformin)
Gemigliptin Tartrate Sesquihydrate 34.45mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.

MFDS item code 202400205 · Approved 2024.01.26 · Insurance code 668903380
Improves blood glucose control in patients with type 2 diabetes
This medication is used as an adjunct to assist in controlling blood sugar in patients with type 2 diabetes when used in combination with Jemigliptin and Metformin. It helps enhance blood sugar control primarily when administered alongside dietary regimes and exercise therapy. This supports more stable management of blood sugar levels. This medication is effectively used to improve blood sugar control in diabetes treatment.
The dose of this medication should be individualized based on the patient's current therapy, efficacy, and tolerability. This medication is generally administered with the evening meal, and the dose is increased gradually to reduce gastrointestinal adverse reactions associated with metformin. Take one 50/500 mg extended-release tablet or one 50/1000 mg extended-release tablet once daily. Patients taking 25/500 mg extended-release tablets, 25/750 mg extended-release tablets, or 25/1000 mg extended-release tablets should take 2 tablets together once daily. For patients not currently receiving metformin who require gemigliptin 50mg, the recommended starting dose of this medication is one gemigliptin 50 mg/metformin 500 mg extended-release tablet once daily, with gradual dose increases to reduce gastrointestinal adverse reactions to metformin. For patients whose blood glucose is not adequately controlled with metformin monotherapy, or with combination therapy of metformin and a sulfonylurea or metformin and insulin, the initial dose of this medication should provide gemigliptin 50 mg once daily and the patient's current metformin dose. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. When this medication is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be necessary to reduce the risk of hypoglycemia. For patients switching from combination therapy with gemigliptin and metformin to this medication, treatment may be started at the current doses of gemigliptin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. The maximum recommended daily dose is gemigliptin 50 mg and extended-release metformin 2000 mg. The safety and efficacy of this medication have not been specifically evaluated in patients switched from other antihyperglycemic agents. Because a change may lead to changes in blood glucose control, any change in treatment for patients with type 2 diabetes should be made with careful monitoring. Swallow this medication whole. Do not crush, cut, or chew it.
This drug is used in the treatment of diabetes and aids in controlling blood sugar levels. When taking this medication, renal function is very important, so it should not be used in patients with impaired kidney function. It should be avoided in cases of severe renal disease, heart failure, or liver dysfunction, as these conditions could pose risks when taking this drug. The drug may cause rare but serious side effects such as lactic acidosis; patients should inform their doctor immediately if symptoms of lactic acidosis such as malaise, muscle pain, difficulty breathing, or abdominal pain occur. Additionally, this drug can induce hypoglycemia, so when taken with other hypoglycemic agents, hypoglycemic symptoms should be closely monitored. Due to the risk of acute pancreatitis, if sudden severe abdominal pain occurs, use should be discontinued immediately and a doctor should be consulted. Pregnant or breastfeeding women are advised to avoid this medication. In the event of surgery or Iodine contrast radioisotope examination, this drug should be discontinued 48 hours before the procedure or examination and can be resumed only after confirming normal kidney function. It is advisable to avoid alcohol consumption while taking this medication, and regular blood tests are needed as vitamin B12 levels may decrease. This drug may cause allergic reactions or hypersensitivity reactions such as skin rash or urticaria in some patients, so any unusual symptoms should be reported to a doctor immediately. Also, some components of this drug may be excreted in the feces, which is a normal phenomenon and unrelated to the drug's effect. Before and during the course of taking this medication, regular kidney and liver function tests should be discussed with a physician, and any unusual symptoms during treatment should prompt immediate consultation with healthcare professionals.
Not everyone experiences these, and they can vary from person to person.
This drug is susceptible to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained at room temperature between 1 degree and 30 degrees Celsius.
Brown oval-shaped extended-release film-coated tablets
30 tablets per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationGemigliptin Tartrate Sesquihydrate 34.45mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationGemigliptin Tartrate Sesquihydrate 34.45mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.